1. Andreani, A., Granaiola, M., Guardigli, M., Leoni, A., Locatelli, A., Morigi, R., Rambaldi, M., and Roda, A., Synthesis and chemiluminescent high throughput screening for inhibition of acetylcholinesterase activity by imidazo[2,1-b]thiazole derivatives.Eur. J. Med. Chem., 40, 1331–1334 (2005).
2. Becker, R., Giacobini, E., Elble, R., Mcllhany, M., and Sherman, K., Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration.Acta Neurol. Scand. Suppl., 116, 19–32 (1988).
3. Bensky, D. and Gamble, A., Materia Medica, Eastland Press, Washington, p. 376, (1986).
4. Bores, G. M., Huger, F. P., Petko, W., Mutalib, A. E., Camacho, F., Rush, D. K., Selk, D. E., Wolf, V., Kosley, R. W., Davis, L., and Vargas, H. M., Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.J. Pharmacol. Exp. Ther., 277, 728–738 (1996).
5. Broadwell, R. D. and Sofroniew, M. V., Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system.Exp. Neuron., 120, 245–263 (1993).